Advertisement
Merck Serono
Subscribe to Merck Serono

The Lead

EMD Serono Appoints New Senior Vice President, Neurology and Immunology

September 2, 2014 9:09 am | News | Comments

EMD Serono announced today that Drew Young has joined the company as Senior Vice President, Neurology and Immunology. In this capacity, he will be responsible for leading the strategic direction of the U.S. Neurology and Immunology franchise, including future products.

Merck Serono Breaks Ground for New Pharmaceutical Manufacturing Facility in China

August 28, 2014 10:48 am | News | Comments

The new facility, which will be the group's second-largest pharmaceutical manufacturing facility...

EMD Serono and Mersana to Develop Next-Generation Antibody-Drug Conjugates

June 24, 2014 8:03 am | News | Comments

EMD Serono and Mersana Therapeutics announced an agreement to collaboratively develop next-...

EMD Serono Enters into Research Agreement with Pfizer and Broad Institute

April 1, 2014 8:04 am | News | Comments

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced they have signed a...

View Sample

FREE Email Newsletter

EMD Serono Strengthens Leadership With New Appointments

February 13, 2014 9:27 am | News | Comments

EMD Serono, Inc. announced today the recent appointments of Gary Zieziula as the company’s Chief Commercial Officer, Allene Diaz as Senior Vice President of Managed Markets, Lisa Buffington as Vice President of US Communications, Alexander Kuta as Vice President and Head of US Regulatory Affairs, and Michael Ruggiero as Vice President of US Government Affairs and Policy.

Biopharm GmbH Enters into Co-Research Agreement with Merck

November 20, 2013 8:47 am | News | Comments

Biopharm GmbH, Heidelberg, announced today that they have signed an agreement with Merck to cooperate with Merck Serono, the biopharmaceutical division of Merck in their research activities directed toward the molecular engineering of a biologic compound for the treatment of osteoarthritis.

Merck Serono and Quintiles Announce Clinical Development Partnership

May 15, 2013 8:06 am | News | Comments

Merck Serono, a division of Merck, Darmstadt, Germany, and Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, today announced a new, five-year clinical development agreement. This strategic collaboration is the first-of-its-kind between a biopharmaceutical company and a biopharmaceutical services provider.

Advertisement

EMD Serono Expands Global Research & Development Hub in Massachusetts

April 18, 2013 10:43 am | News | Comments

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today the continued expansion of the company’s presence in the United States, resulting in an estimated 20% increase in EMD Serono’s employee base from last July to the end of 2014.

Aeterna Zentaris Transfers Cetrotide Manufacturing Rights to Merck KGaA

April 17, 2013 7:57 am | News | Comments

Aeterna Zentaris Inc. today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide product. The principal effect of such agreements is to transfer manufacturing rights and to grant a manufacturing license for Cetrotide to a subsidiary of Merck KGaA of Darmstadt, Germany, in all jurisdictions.

Columbia Labs Extends Agreement with Merck Serono for CRINONE Through 2020

April 9, 2013 7:56 am | News | Comments

Columbia Laboratories, Inc. has amended its license and supply agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for CRINONE ® (progesterone gel) through May 2020, representing an extension of five years beyond the current term, which was due to expire in May 2015.

EMD Serono: Phase III Trial of Cilengitide Did Not Meet Primary Endpoint in Patients With Newly Diagnosed Glioblastoma

February 25, 2013 8:04 am | News | Comments

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III CENTRIC a trial of the investigational integrin inhibitor cilengitide did not meet its primary endpoint of significantly increasing overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy).

Dr. Reddy's Laboratories Ltd. and Merck Serono Announce Collaboration to Develop and Commercialize Biosimilars

June 6, 2012 4:02 am | News | Comments

Dr. Reddy's Laboratories Ltd. and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions.  

Advertisement

Study: Use of Drug Following First Sign of Possible MS Reduces Likelihood of Progression to MS

April 20, 2012 4:23 am | News | Comments

People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial.

Merck and Threshold to Co-Develop and Commercialize Hypoxia-Targeted Drug

February 3, 2012 3:36 am | News | Comments

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

Ablynx and Merck Serono Expand Their Partnership Into Osteoarthritis

November 9, 2011 3:58 am | News | Comments

ABLX today announced that it has further expanded its relationship with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and entered into a third agreement to co-discover and co-develop Nanobodies against two targets in osteoarthritis.

Merck Serono Returns Rights for Safinamide to Newron

October 21, 2011 4:22 am | News | Comments

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has decided to return all rights for safinamide to Newron Pharmaceuticals S.p.A.

Merck Serono and Ono Pharmaceutical Form Collaborations to Develop Oral Multiple Sclerosis Drug and Cancer Immunotherapy

October 4, 2011 4:05 am | News | Comments

 Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the signature of two separate agreements with Ono Pharmaceutical Co., Ltd., Osaka, Japan to strengthen its multiple sclerosis and cancer franchises.

Advertisement

Merck Serono Acquires Rights to PI-2301 Program for Multiple Sclerosis

September 19, 2011 4:10 am | News | Comments

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has acquired worldwide exclusive rights to PI-2301, an experimental drug for multiple sclerosis, previously developed by Peptimmune Inc. PI-2301 has completed Phase 1b in multiple sclerosis and is ready to initiate phase 2 clinical trials.

EMD Serono Appoints New President

July 14, 2011 6:07 am | News | Comments

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that James Hoyes has been appointed President.

Merck Serono Receives European Approval for Three Pre-filled, Ready-To-Use Pen Injectors for Fertility Treatment

July 5, 2011 4:32 am | News | Comments

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has announced that the European Commission (EC) has granted an approval for three pre-filled, ready-to-use pen injectors for fertility treatment.

EMD Serono’s Massachusetts Facility Receives Gold LEED® Rating

April 26, 2011 7:36 am | News | Comments

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that the company's state-of-the-art research center in Billerica, MA, is LEED® Gold certified under the U.S. Green Building Council and verified by the Green Building Certification Institute (GBCI).

Merck Serono Receives Complete Response Letter from FDA on Cladribine Tablets NDA

March 2, 2011 3:49 am | News | Comments

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, Merck Serono’s proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS).

EMD Serono Opens State-of-the-Art Research Center in Billerica, MA

February 10, 2011 3:44 am | News | Comments

EMD Serono, Inc. has opened a state-of-the-art research center in Billerica, MA, establishing it as a "hub" within the Merck KGaA research organization.

Merck Serono and Domain Therapeutics to Develop Drugs for Parkinson's Disease

January 17, 2011 3:21 am | News | Comments

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that an exclusive development and licensing agreement with Domain Therapeutics, Strasbourg, France, was signed to develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson's disease and other neurodegenerative diseases.

Merck and sanofi-aventis to Jointly Investigate Novel Combinations Against Cancer

December 17, 2010 3:37 am | News | Comments

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Merck, has signed a worldwide research and development agreement with sanofi-aventis U.S. Inc., under which Merck Serono and sanofi-aventis U.S. Inc. will collaboratively investigate novel experimental combinations of agents that could block specific pathways in cancer cells.

Ready-to-Use Formulation of Recombinant Growth Hormone Saizen Recommended for Approval in Europe

November 15, 2010 3:33 am | News | Comments

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has successfully completed the Decentralized Procedure (DCP) allowing for approval of Saizen(R) Solution For Injection (somatropin) in the 18 participating Member States

EMA Issues Negative Opinion Regarding Merck's MS Treatment

September 24, 2010 4:53 am | News | Comments

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion regarding the marketing authorization application (MAA) for Cladribine Tablets as a treatment for relapsing-remitting multiple sclerosis (MS).

FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS

July 28, 2010 4:26 am | News | Comments

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the FDA has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).

Merck Serono's Cladribine Tablets for MS Approved in Russia

July 12, 2010 4:25 am | News | Comments

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the Russian Federal Service on Surveillance in Healthcare and Social Development has become the first government agency to grant marketing approval to Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS). Cladribine Tablets will be available in Russia under the trade name Movectro(R).

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading